3. Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE: PFE) brings a documented AI drug-discovery initiative to this selection. On January 8, 2026, Boltz announced a collaboration to develop biomolecular AI models and generative workflows for Pfizer’s small-molecule and biologics research. The agreement includes refining models using Pfizer’s historical data, while Pfizer retains ownership of compounds discovered or developed with the platform’s support. prnewswire.com
The potential business benefit is better decision-making earlier in drug development. Identifying promising candidates and avoiding weaker ones could improve research productivity, although those benefits must ultimately appear in clinical progress and financial results.
Pfizer ranks third because it combines a direct AI initiative with an established pharmaceutical business. Its limitation is the distance between a promising discovery tool and an approved, commercially successful medicine. AI-assisted research still faces clinical failure, regulatory review, and development costs.
